NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity
1/3
NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for
Obesity
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - NeonMind Biosciences Inc. (CSE: NEON)
(OTC: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that on March 10, NeonMind engaged
Certara®, the global leader in model-informed drug development to provide strategic integrated drug
development support for the investigation of NeonMind's psilocybin based drug candidates for the treatment of
obesity.
Figure 1: NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7646/76845_neon2.jpg
NeonMind is exploring psilocybin as an innovative treatment approach to support weight loss. NeonMind's first
drug candidate aims to use synthetic psilocybin to enhance a patient's ability to alter behaviours that cause
weight loss through psychedelic-assisted cognitive therapy. The second drug candidate proposes low dose
synthetic psilocybin as a treatment to suppress appetite.
"Certara has the expertise, technology and network to further our drug development efforts to help us achieve our
goals of progressing psilocybin-based weight loss treatments through the rigorous drug development process,"
said Rob Tessarolo, President & CEO of NeonMind. "We are assembling world-class R&D capabilities dedicated
to creating a dossier of scientific evidence to support regulatory approval for these novel treatments that can
positively impact millions of people."
2/3
The typical roadmap to regulatory submission for a product involves a sponsor like NeonMind to complete a
complex interconnected sequence of evaluations on the product's quality (CMC - chemistry, manufacture, and
controls), preclinical efficacy, safety pharmacology and toxicology, and preclinical and clinical pharmacological
characterization. The evaluations and their sequence are established in an integrated drug development plan by a
cross-functional team of experts.
Pursuant to the engagement, NeonMind with access to global leaders in drug development strategy, due
diligence, toxicology, clinical pharmacology, regulatory science, and the full spectra of drug development subject
matter experts across Certara.
Certara provides biosimulation software to transform traditional biopharmaceutical R&D with a scientific team
that has more than 3,500 years of collective drug discovery and development experience. Since 2014, 90% of
new drug and biologic approvals by the US FDA have been received by Certara's customers.
About NeonMind Biosciences Inc.
NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's first drug
candidate aims to use synthetic psilocybin to enhance a patient's ability to adopt behaviours that cause weight
loss through psychedelic-assisted cognitive therapy. The second drug candidate proposes low dose synthetic
psilocybin as a treatment to suppress appetite.
NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is
involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs psilocybin as an
agonist to the 5-HT2C receptor, which controls appetite.
NeonMind has an intellectual property portfolio which includes uses of psychedelic compounds for the treatment
of compulsive eating disorder, obesity and related complications, to aid in weight loss, reduce food cravings,
decrease food intake and to alter diet. NeonMind has filed 10 US provisional patent applications for psychedelic
compounds, of which 2 have been converted to PCT applications, with potential rights in 152 countries.
NeonMind's first PCT patent application covering the administration of psilocybin and its analogs to treat obesity
and compulsive eating disorder has a priority date of December 4, 2019. The anticipated patent protection expiry
of these pending patents is 2041.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
Edge Communications
Tel: 1-866-318-6874
Renmark Financial Communications Inc.
Melanie Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or 212-812-7680
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
3/3
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements
relate to future events or NeonMind's future performance. The use of any of the words "could", "expect",
"believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information and are based on NeonMind's current belief
or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the
development of its intellectual property and other steps in its preclinical and clinical drug development
constitute forward-looking information. Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-
looking information. The statements made in this press release are made as of the date hereof. NeonMind
disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as may be expressly required by applicable
securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76845